Although more work remains to be done with regard to the regulatory mechanism and functional role of TET2/PD-L1 axis in the anti-tumor immunity, our findings suggest that targeting TET2 or HDAC1/2 might be a potential combination strategy for the anti-PD-1/PD-L1 immunotherapy treatment of breast cancer. The gene discussed is TET2; the disease is breast carcinoma.